Nightstar Therapeutics Limited (NITE) Receives a Buy from Mizuho Securities


In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Nightstar Therapeutics Limited (NASDAQ: NITE), with a price target of $24. The company’s shares closed yesterday at $21.31.

Yang commented:

“We attended Nightstar’s R&D Day yesterday where management presented preliminary data from the dose escalation study of NSR-RPGR for the treatment of X-Linked Retinitis Pigmentosa. We were encouraged by early signals observed in all cohort 3 patients and 2/6 patients in cohorts 4 and 5. However, the therapeutic dose to be taken into the upcoming expansion study remains to be determined as higher dose responders required a second course of steroids to control mild sub-retinal inflammation. The next important catalyst for the shares will be 2Q19 with six-months follow-up data from the dose escalation study. We maintain our Buy rating on the stock.”

According to TipRanks.com, Yang is a top 100 analyst with an average return of 25.1% and a 55.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.

Currently, the analyst consensus on Nightstar Therapeutics Limited is a Strong Buy with an average price target of $33.25, a 56.0% upside from current levels. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $40 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $29.55 and a one-year low of $10.01. Currently, Nightstar Therapeutics Limited has an average volume of 128.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts